of weight loss on COPD-associated comorbidities in obese COPD
Negewo1, Peter Gibson1,2, Lisa Wood1, Katherine
Baines1 and Vanessa
Research Centre for Healthy Lungs and Hunter Medical Research
Institute, The University of Newcastle, New
South Wales, NSWAustralia,
of Respiratory and Sleep Medicine, John Hunter Hospital, New
South Wales, NSWAustralia
The effect of weight loss on COPD-associated comorbidities in obese
COPD patients is unknown.
test the hypothesis that an intervention targeting obesity could
improve markers of comorbidities in obese COPD.
secondary analysis of a before-after clinical trial (McDonald, V.M. et
al. Respirology 2016 doi:10.1111/resp.12746), where 28 obese COPD
patients (BMI≥30kg/m2) completed a
12-week dietary restriction and resistance training, was performed.
This abstract reports the change in comorbidity markers
Mean (SD) age was 67.6 (6.3) years, 17 were males and FEV1%
predicted was 61.6 (17.1)%. Mean BMI was 36.1 (4.5)kg/m2
at baseline and was reduced by 2.4kg/m2
(p<0.0001). The most common comorbidities included hypertension
(53.6%), hyperlipidaemia (46.4%), depression (32.1%) and diabetes
(14.3%). Weight loss improved cardio-metabolic markers and depression
score, primarily in participants with elevated basal levels of these
Weight loss with
exercise training results in improvements in multiple markers of
comorbidities in obese COPD.
cholesterol (≥5.5mmol/L) n=7
BP (≥140mmHg) n=15
BP (≥90mmHg) n=5
blood glucose (≥6.1mmol/L) n=6
Model Assessment-Insulin Resistance (≥1.4) n=8